-
Drug Discovery
-
Preclinical Research
-
Collaborate With Us
-
Resources & Support
-
Publications
-
Get inspired by peer-reviewed publications of our scientists, partners, and customers around the globe.
-
-
Blogs
-
Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
-
-
Case Studies
-
Get inspired by research done by our scientists, partners, and customers around the globe.
-
-
Webinars & Events
-
Applications
-
-
About Mimetas
-
About us
-
Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
-
-
Contact us
-
Locations
-
Careers
-
-
News
History
In the picture from left to right, are Paul Vulto (CEO), Jos Joore (CEO), Bas Trietsch (CTO), and Jacquelien ten Dam (CFO). Together they are forming the management team of MIMETAS. Paul, Jos, and Bas founded MIMETAS in 2013 in Leiden, the Netherlands. Since then, Paul and Jos have been CEOs, whereas Bas is now serving as CTO. In that same year, MIMETAS incorporated her US-branch in Gaithersburg (MD). Also, the Dutch-Belgian biotech company Galapagos (Euronext & NASDAQ: GLPG) became MIMETAS’ launching customer. MIMETAS expanded rapidly over the years. The company is now working with nearly all major pharmaceutical companies and many top-tier academic institutes. In 2018, MIMETAS opened a subsidiary in Tokyo to expand its presence in Asia. In 2019, the management team has been expanded and strengthened with the addition of Jacquelien ten Dam, serving as CFO.
Today, MIMETAS counts over 100 employees in four sites in the Netherlands, USA, and Japan.
In 2014, MIMETAS raised a Series A investment round of 5.6 million USD, followed by a Series B round of 21 million USD in 2018
Mission
MIMETAS strives to contribute to groundbreaking therapies with unique human disease biology, revealed by robust, screenable assays in the most versatile technology platform.
Vision
We believe that phenotypic tissue- and disease modeling is at the heart of 21st-century therapy development.
Board of Directors
Chairman - Dhaval Patel
Executive board members
Jos Joore - CEO, Mimetas
Paul Vulto - CEO, Mimetas
Non-executive board members
André Hoekema - Galapagos
David Devigne - OMX Europe Venture Fund
Edward Willems - Gold Nest Private Capital
Eric van der Putten - Aglaia Oncology Funds
Scientific Advisor - Patrice Denèfle
Core Values
Highly talented, friendly, and energetic people from all over the world have found their way to MIMETAS. It is these people that embody our core values by their sheer character and qualities. We call this ‘MIMETAS-do’. It's the way we roll.
At one of our company retreats, we asked our colleagues to put MIMETAS-do into words. And as you know: a picture is worth a thousand words. Check the image for the result.
Wondering what it's like to work with or at MIMETAS? Try us and find out.
Living innovation
Celebrate good times.
Mieke Doornbos
Vice President
Sales & Marketing
Vice President
Sales & Marketing
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform
James Sabry, Global Head
Roche Pharma Partnering
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "
Cezmi Akdis
Director SIAF
University Zurich
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.
Philip Hewitt
Head of Early Investigative Toxicology
Merck KGaA
Chiwan Chiang
Field Application Specialist
A day without
laughter is a day wasted.
laughter is a day wasted.
Pioneering to the best solutions for scientific discovery.
Frederik Schavemaker
Product Design Engineer
Product Design Engineer
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data
Scientist
From a top pharma
Jos Joore
CEO
We want to
empower research on complex tissue biology.
empower research on complex tissue biology.
Engaging, playful and innovative.
Liis Rannamae
Technician
Technician
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!
Scientist
From a top pharma
Nienke Wevers
Senior Scientist
Nothing ventured, nothing gained.
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.
Scientist
From a top commercial organization
Henriëtte Lanz
Director of Model Development
It should be
mandatory to
socialize with colleagues.
mandatory to
socialize with colleagues.
Organoplates opened avenues that were before considered unreachable
Laura Perin, PhD
Children’s Hospital Los Angeles
Bas Trietsch
Chief Technology Officer
We try to help
each other
as a team.
each other
as a team.
The OrganoReady model has been very useful for fast screening of novel gene therapy related technologies in our company. The membrane-free fluidics is a high throughput screening tool to monitor a transfer of antibodies through the blood brain barrier.
Svetlana Pasteuning
VectorY B.V., Netherlands
Jacquelien Ten Dam
Chief Financial Officer
It always seems impossible until it’s done.
Paul Vulto
CEO
Leveraging who you are, is the key to making a difference!
Tina Thakkar
Associate Director of Sales
It is not really work if you are having fun.
Liis Rannamäe
Laboratory Technician
Can be summarized in three words - engaging, playful, and innovative.
